• Explore /
  • Poster
  • / Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.

Abstract Video & Slides Poster

Authors

null

Paul M. Barr

Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

Paul M. Barr , John N. Allan , Tanya Siddiqi , William G. Wierda , Constantine Si Lun Tam , Carolina D. Moreno , Alessandra Tedeschi , Edith Szafer-Glusman , Cathy Zhou , Chris Abbazio , James P. Dean , Anita Szoke , Paolo Ghia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT02910583

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7535)

DOI

10.1200/JCO.2023.41.16_suppl.7535

Abstract #

7535

Poster Bd #

86

Abstract Disclosures

Similar Posters

First Author: Akash Mukherjee

First Author: Von Tresckow Julia

First Author: Ömür Gökmen Sevindik

First Author: Jacqueline Claudia Barrientos